AGENUS INC. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Agenus Inc. (Nasdaq: AGEN) on January 14, 2026, covering events occurring on January 8, 2026. The filing addresses Item 5.02 regarding the appointment of certain officers.
Key Financial Metrics
The filing does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly focused on corporate governance and personnel changes.
Material Changes
The primary material change reported is the appointment of two key financial officers effective January 8, 2026:
- Interim Chief Financial Officer: Dr. Garo Armen, the Company's Chairman and CEO, was appointed as interim CFO and Principal Financial Officer. He co-founded the company in 1994 and has a background in biopharmaceutical restructuring and investment banking.
- Principal Accounting Officer: Austin Charette, previously Senior Director of Financial Reporting and Compliance, was appointed as Principal Accounting Officer. He joined Agenus in 2017 and previously worked at Deloitte & Touche LLP.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Regarding the new appointments, the Company stated there were no new compensatory arrangements or modifications to existing ones. Dr. Armen continues to receive his base salary and potential bonuses in Agenus stock rather than cash. No family relationships or related party transactions were disclosed.
Investor Verification Checklist
- Verify the effective date of the interim CFO appointment (January 8, 2026).
- Confirm that no new compensation agreements were executed for Dr. Armen or Mr. Charette.
- Review subsequent filings for the appointment of a permanent CFO, as Dr. Armen's role is interim.
- Check the Company's latest 10-K or 10-Q for the most recent financial position, as this 8-K contains no financial metrics.